Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.56 |
| ▸ | ACMSD | Q8TDX5 | 3/20 | 0.54 |
| ▸ | HNF4A | P41235 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315969 | 0.91 | HNF4A (0.54) | ACLYACMSDHNF4AHDAC1HDAC2 | |
| SCHEMBL1318525 | 0.90 | ACLY (0.67) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1316020 | 0.89 | HDAC1 (0.62) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1316465 | 0.88 | HDAC1 (0.63) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1316946 | 0.87 | HDAC1 (0.62) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1317299 | 0.85 | HDAC1 (0.46) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL13206537 | 0.84 | ACLY (0.59) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1315416 | 0.83 | ACLY (0.59) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL1316356 | 0.83 | ACLY (0.51) | ACLYACMSDHNF4ADHFRMCL1 | |
| SCHEMBL2272453 | 0.82 | ACLY (0.63) | ACLYACMSDHNF4ADHFRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | ACLY 295/4885ACMSD 74/4885HNF4A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.